Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 0.68 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584430 | 1.00 | GRM5 (0.68) | GRM5ACACBHSD17B1CASP1CASP7 | |
| SCHEMBL10190633 | 0.92 | GRM5 (0.70) | GRM5HSD17B1 | |
| SCHEMBL10190652 | 0.89 | GRM5 (0.61) | GRM5ACACBHSD17B1CASP1CASP7 | |
| SCHEMBL10190651 | 0.82 | GRM5 (0.67) | GRM5ACACBHSD17B1CASP1CASP7 | |
| SCHEMBL10190650 | 0.82 | GRM5 (1.00) | GRM5ACACBCASP1CASP7HSD17B10 | |
| SCHEMBL504636 | 0.81 | GRM5 (1.00) | GRM5 | |
| SCHEMBL29739073 | 0.79 | GRM5 (0.72) | GRM5ACACBCASP1CASP7HSD17B10 | |
| SCHEMBL24570503 | 0.79 | GRM5 (0.72) | GRM5ACACBCASP1CASP7HSD17B10 | |
| SCHEMBL10190641 | 0.77 | GRM5 (0.66) | GRM5HSD17B1 | |
| SCHEMBL10190640 | 0.75 | GRM5 (0.70) | GRM5HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685313-A | Indanyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022140555-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |